New Job Opportunity

February 06, 2026 | New Job Opportunity

Precision Opens Singapore Hub to Strengthen Asia-Pacific Clinical Operations

Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development, has announced the opening of a new office in Singapore. This strategic expansion strengthens Precision's significant presence across the Asia-Pacific (APAC) region, serving as a crucial hub for enhanced client support and accelerated regional growth. "This expansion, particularly with our new Singapore hub, signifies a major step in deepening our operational capabilities and localized expertise across APAC," said Jing Ping Yeo, Vice President, Clinical Operations. "By expanding in critical markets like Singapore, we're providing our clients with greater assurance on trial oversight and delivery, accelerating site activation and ultimately ensuring more efficient and higher-quality execution of complex, biomarker-driven clinical programs for patients worldwide." Singapore's central location and sophisticated infrastructure make it ideal for growing Precision's regional presence, including Mainland China, Hong Kong, India, South Korea, Taiwan and Australia. Through its expanded footprint, embedded senior leaders and a dedicated team of over 500 employees, Precision underscores its commitment to navigating the complexities of regional drug development and commercialization. For its global partners, APAC expansion solidifies Precision as a single, unified CRO, eliminating the friction and complexity of managing multiple partners while offering streamlined oversight, clearer lines of accountability, and greater assurance regarding the quality and consistency of trial delivery. Conversely, for regional clients, this enhanced capability empowers them to effectively bring their ground-breaking therapies to global development pathways across the U.S. and Europe. The Precision team features oversight from recognized leaders in several regions of APAC, such as Dr. Yeo, who also chairs the Drug Information Association (DIA) Singapore Advisory Committee and the Singapore Clinical Research Professionals Association (SCRP) and serves on the Program Committee for DIA-Asia, and operational capabilities in the region. "The new Singapore office is a strategic pillar in our mission to be the unified partner for precision medicine development, both globally and within the dynamic APAC landscape," said James Cheong, Senior Vice President, APAC. "This strategic hub facilitates the seamless integration of our extensive global expertise with local insights from our regional teams, positioning us to deliver accelerated solutions and deeper support to our clients." "The opening of our Singapore office is a pivotal moment that significantly strengthens Precision's already robust APAC footprint," said Daisy DeWeese-Gatt, President, Clinical Solutions, Precision for Medicine. "By better integrating diverse APAC data and patient populations, we can advance new medicines faster, ensuring therapies are better tailored and more representative of real-world diversity for patients globally with high unmet needs."

February 05, 2026 | New Job Opportunity

Slingshot Scales Global Growth with UK and EU Expansion

Slingshot Biosciences, the pioneer of synthetic cell mimic technology for flow cytometry controls, announced its further expansion into the United Kingdom and European Union markets. This investment provides the product innovators in the region with broader access and faster adoption of Slingshot's reproducible, premium-quality biomarker controls in their cell-based assay development programs. The company's aggressive growth continues, driven by the broad adoption of its cell-mimic technology by hundreds of pharmaceutical companies, biotechnology firms, contract research organizations (CROs), clinical diagnostics laboratories, and academic medical centers worldwide. "The United Kingdom and European Union represent one of the world's most dynamic and innovative life sciences markets," said Glenn Bilawsky, Chief Executive Officer of Slingshot Biosciences. "...these regions are home to top-tier research institutions, leading cell therapy companies, and global pharmaceutical firms that share our dedication to advancing scientific rigor and reproducibility. We're excited about the rapid adoption of our technology in these markets and are expanding our commitment to researchers and manufacturers in their mission to develop life-saving therapies faster and more reliably." Slingshot Biosciences' proprietary platform delivers precision-engineered synthetic cell mimics that eliminate the variability, fragility, and operational inefficiency inherent in traditional biological controls. Lot-to-lot consistency achieves coefficients of variation as low as 0.1%. Researchers have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies. The company's synthetic cell-mimic controls enable researchers to achieve reproducible results across multiple sites and instruments, a critical requirement for clinical trials, cell therapy manufacturing, and rapid, successful regulatory submissions.

February 02, 2026 | New Job Opportunity

Lilly to Create 850 Jobs with New PA Manufacturing Hub

Eli Lilly and Company announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new U.S. manufacturing site Lilly has announced since February 2025, as part of its commitment to bolster domestic medicine production. Lilly will bring 850 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 2,000 construction jobs. The site will be operational in 2031. "Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we're expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines. We're creating high‑quality jobs and collaborating across the region—with suppliers, educators, and workforce‑development partners—to make critical medicines in the U.S.," said David A. Ricks, Lilly chair and CEO. "That's our commitment—to patients, to our new Pennsylvania home and to our country." Expanding Lilly's U.S. manufacturing presence in Pennsylvania will boost the Lehigh Valley economy. For every dollar Lilly invests, it estimates up to four dollars in additional local economic activity. Also, for each manufacturing job created, several more will be generated in related sectors like supply chain, logistics and retail. "When we announced our Economic Development Strategy here in the Lehigh Valley two years ago, we set out to win historic, life-changing deals like the one we're announcing with Lilly today," said Governor Josh Shapiro. "Before I took office, Pennsylvania wasn't even in the conversation for major investments like this, but thanks to our work to cut red tape, invest in site development, and expand our workforce, our Commonwealth is now competing—and winning—on a national scale. Lilly's commitment to the Lehigh Valley and to Pennsylvania will bring billions of dollars of investment and hundreds of good-paying jobs, solidifying our position as a leader in the growing life sciences industry." The Lehigh Valley site, located in Fogelsville, Pennsylvania, was selected from more than 300 applications, partly based on its proximity to STEM universities, its technical manufacturing economy, and its existing infrastructure. In addition, with increasing demand from the biotech industry, the region offers convenient access to utilities, transportation, and favorable zoning and incentives. Lilly will utilize advanced technologies, including AI, machine learning, integrated monitoring, and data analytics, to enable efficient operations and a reliable supply of medicine. The company will partner with local universities and invest in education across Pennsylvania to develop talent. "Lilly Lehigh Valley—our newest injectable medicine and device manufacturing facility—will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "Our investment here is more than just building a facility—it's about building a shared future with the people and communities of the Commonwealth. Through meaningful partnerships in Pennsylvania, we're committed to fostering collaboration, driving innovation, advancing environmental stewardship, and creating lasting positive impact that extends far beyond our facility walls."

February 02, 2026 | New Job Opportunity

DHL Scales Healthcare Logistics with Singapore Expansion

DHL Group has announced the expansion of its life sciences arm—DHL Health Logistics—with the development of a €10 million Pharmaceutical Hub in Singapore. This investment bolsters regional Life Sciences and Healthcare (LSHC) infrastructure. As a global leader in international logistics, DHL Express provides extensive network connectivity and operational expertise. In the life sciences and healthcare sector, the requirement for reliable and secure logistics continues to grow as global supply chains become increasingly complex. Addressing the Growing Needs of a Modern Healthcare Supply Chain The demand for specialised healthcare logistics is rising, driven by global health challenges, an ageing population, and the development of advanced therapies. In Singapore, the biomedical sector produces goods valued at nearly S$38 billion for global markets. The industry requires a health logistics infrastructure capable of accommodating the increasing volume and complexity of life-saving products distributed from regional hubs to the rest of the world. In the modern healthcare supply chain, every step impacts patient well-being and critical research. Innovation in medical shipping is no longer optional; maintaining stringent temperature control for pharmaceuticals and navigating the regulatory demands of medical devices is critical. By aligning with Singapore's strategic vision, DHL provides the precision and reliability to support scientific progress and ensure that products are handled as required by the healthcare ecosystem. DHL's Reach in Life Sciences & Healthcare DHL leverages an extensive global network spanning over 220 countries and territories to facilitate seamless international logistics. Through DHL Health Logistics and its services, the group utilises dedicated healthcare hubs and warehouses within a GDP-compliant infrastructure. This allows the group to support the global healthcare ecosystem with a combination of high-capacity transport and local handling. Supported by a medical courier framework, DHL Health Logistics is optimised for urgent medical needs through priority delivery and time-definite collection schedule. All shipments are managed by certified specialists to ensure adherence to international healthcare standards and rigorous quality management certifications. Setting Up the Next Vantage Point for Healthcare Logistics DHL has strengthened its healthcare logistics capabilities in Singapore with the addition of the €10 million pharmaceutical hub, featuring specialised temperature zones and GMP-compliant infrastructure. Located near Tuas Biomedical Park, this facility reinforces Singapore's position as a strategic hub for Asia-Pacific, offering efficient connectivity to Changi Airport and Tuas Mega Port. These investments are part of a broader commitment to invest €500 million into regional health logistics by 2030, supporting resilience in global healthcare supply chains. Leaving a Positive Impact on Life Sciences The expansion of DHL Health Logistics is intended to support improved patient outcomes by facilitating timely delivery of critical medicines and medical devices. By strengthening its infrastructure, DHL provides the reliability required for shipping medicine and healthcare products through every stage of the supply chain: Pharmaceutical Logistics: DHL maintains GxP compliance and operational efficiency through strategic investments like the new Singapore Pharma Hub, which manages demand surges and large-scale vaccine distribution. Clinical Trial Logistics: The network provides specialised handling for Investigational Medicinal Products (IMP) and biological samples, supported by a global infrastructure of GMP-compliant depots and temperature-monitored shipping. Medical Device Logistics: "Device Final Mile" facilitates the delivery of medical devices and equipment directly to healthcare facilities. Aftermarket support maximises equipment uptime by supplying spare parts and repairs. Speciality Pharmaceutical Logistics: DHL ensures cold chain integrity across a spectrum of requirements, from ambient to cryogenic (-196°C) environments, utilising real-time monitoring to mitigate risks for sensitive shipments. Consumer Healthcare Logistics: To maintain product availability, DHL utilises automation and omnichannel fulfilment to bridge the gap between manufacturers and retail platforms. Aid and Relief Logistics: Leveraging a global network and dedicated Control Towers, DHL provides rapid response capabilities and procurement expertise for humanitarian missions and disaster relief.

January 22, 2026 | New Job Opportunity

Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China

Sisram Medical Ltd, a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, announced that its wholly-owned subsidiary, Sisram Medical China (Tianjin) Ltd., has entered into a memorandum of understanding ("MOU") with Sinmait Medical Technology (Beijing) Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. This MOU establishes a framework for cooperation aimed at enhancing localization efforts in China. This partnership is poised to accelerate Sisram's strategic implementation and business expansion in the Chinese market, strengthen the resilience of its global supply chain, and solidify the Company's position as a leader in innovation and market presence in medical aesthetics, both locally and globally. By deepening its partnership with Fosun Pharma, Sisram will leverage Sinmait's advanced production capabilities and local expertise to establish a robust manufacturing hub in China, initially focused on localized production of Energy-Based Devices (EBD) and setting the stage for expansion into a broader product portfolio. The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production, sophisticated logistics, and advanced research and development. "This collaboration with Fosun Pharma elevates Sisram's localization strategy in China to a new level," said Mr. Lior Dayan, Chairman and Executive Director of Sisram Medical. "The core significance of this partnership lies in building a comprehensive, resilient, and competitive localized ecosystem. It represents a key milestone in our vision of 'In China, for Global,' setting the foundation for scalable, sustainable growth and long-term value creation." As combined therapies gain traction in China's medical aesthetics sector, the synergistic development and localized manufacturing of EBD alongside other product offerings will significantly enhance the portfolio's overall effectiveness, providing Chinese consumers with a wider array of superior and accessible domestic wellness solutions.

January 22, 2026 | New Job Opportunity

Daiichi Sankyo Strengthens Canada Presence, Driving High-Value Healthcare Jobs

Daiichi Sankyohas further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology. "Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care." "Our government is protecting Ontario by cutting taxes and red tape, saving businesses $12 billion a year so that we can drive economic growth and welcome investments just like this one. Daiichi Sankyo's investment will help create good-paying jobs, strengthen our economy and reinforce Ontario's position as a world-class hub for innovation and health research. I want to thank Daiichi Sankyo for their confidence in Ontario's incredible workers," said Ontario Premier Doug Ford. "This opening marks the beginning of an exciting new chapter for Daiichi Sankyo in Canada where we are further establishing our presence in Toronto as we continue to expand access to our oncology portfolio," added Fatih Yedikardeş, Country Manager, Canada, Daiichi Sankyo. "This expansion means improving access to our medicines and strengthening our partnerships with healthcare professionals and the broader life sciences community in Canada." "As the largest life sciences jurisdiction in Canada, Ontario is a prime location for domestic and international pharmaceutical companies to establish their headquarters and advance their research from lab to market. We congratulate Daiichi Sankyo on the opening of their new Canadian headquarters here in Toronto and look forward to seeing the next chapter of their biomedical innovation that will leverage Ontario's highly skilled workforce and R&D capabilities," said Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade. Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital. "By establishing their Canadian headquarters in Toronto, Daiichi Sankyo is affirming Ontario's place as a hub of health innovation. This investment in Ontario will advance access to innovative cancer medicines for Ontario families, building on our government's actions to date to connect patients to cutting-edge, life-saving cancer drugs faster," added Sylvia Jones, Ontario Deputy Premier and Minister of Health.

January 20, 2026 | New Job Opportunity

Alcami Expands RTP Footprint with $6.7M Durham Lab Facility Acquisition

Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), has acquired a 37,000-square-foot facility at 4620 Creekstone Drive in Durham, North Carolina. This $6.7 million investment strengthens Alcami's presence in the Research Triangle region and supports the company's continued expansion of advanced laboratory services. Located in the heart of Research Triangle Park (RTP), the two-story facility will serve as a hub for Alcami's growing analytical and development capabilities. In October, Alcami announced plans for a major lab expansion at this site, scheduled for completion later this year. This expansion will enhance Alcami's ability to support a broad range of complex therapeutics, including biologics, peptides, proteins, oligonucleotides, and cell and gene therapy drug substances. "This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics," said Katie Schlipp, President, Lab Operations at Alcami. "By expanding our analytical lab capabilities in RTP, we're able to support innovators in bringing life-changing therapies to patients faster and more reliably." The Creekstone Drive facility complements Alcami's established lab operations, sterile fill-finish manufacturing, and cGMP storage in the RTP area, as well as its remaining U.S.-based network of facilities. These strategic investments position Alcami to provide advanced solutions that streamline drug development and mitigate supply chain risks. Alcami recently announced the qualification of a third sterile fill-finish line at its RTP campus, bringing its total network to five qualified GMP-compliant lines for clinical and commercial manufacturing. Together, these expansions reinforce Alcami's commitment to advancing drug development and ensuring reliable supply for life-saving therapies.

January 20, 2026 | New Job Opportunity

BorderPlus Launches AI-Powered Nurse Companion at the German Nursing Career Fair in Kochi

BorderPlus, an international career mobility platform enabling ethical and structured global career pathways for healthcare professionals, announced the launch of its AI-powered Nurse Companion at the German Nursing Career Fair in Kochi. The launch marks a significant step in empowering nursing students in Kerala with clear, personalised, and credible guidance on global nursing careers, particularly in Germany. Designed as a language-first learning tool, the AI-powered Nurse Companion helps nursing students build real-world German language proficiency through immersive practice. The companion enables nurses to experience over 350+ hours of simulated, real-life interactions in German healthcare and everyday settings, allowing them to effectively “live in Germany” linguistically before they physically move. The AI Nurse Companion is available exclusively to students enrolled at the BorderPlus Finishing School, ensuring structured, guided language immersion as a core part of their preparation journey. The German Nursing Career Fair brought together aspiring nurses, language experts, and German healthcare stakeholders, and saw participation from over 150+ attendees, highlighting both the strong interest in overseas opportunities and the growing need for transparent, trustworthy information. The event had a keynote address by Joseph Annamkutty Jose, renowned motivational speaker, author, and radio personality, who encouraged nurses to think beyond short-term outcomes and focus on clarity, preparation, and sustained professional growth. Speaking at the event, he said, “Building a successful career in nursing requires more than ambition. It takes consistent effort, dedication, and the courage to step outside your comfort zone. Those who invest time in preparation, embrace challenges, and approach each decision thoughtfully are the ones who advance professionally and create lasting impact for their families and communities. Clarity, persistence, and resilience are the keys to turning opportunities into meaningful, long-term careers.” During the fair, BorderPlus outlined its end-to-end enablement model spanning preparation, finishing school, ethical placement, and on-ground integration. The newly launched AI Nurse Companion strengthens this ecosystem by offering nurses consistent, unbiased guidance at every stage of their journey, helping them avoid fragmented or unrealistic pathways. A key highlight of the fair was a virtual interaction with German healthcare stakeholders, who shared first-hand insights into employer expectations, professional standards, workplace culture, and integration timelines. The session helped understand the German healthcare system and gave nurses a realistic understanding of what it takes to build successful careers in Germany. Commenting on the Career Fair, Mayank Kumar, CEO & Co-founder, BorderPlus, said, “Our aim in bringing people together at the German Nursing Career Fair was to create space for clear, honest conversations about working as a nurse in Germany. These are life-changing decisions, and when nurses have the right information, the impact extends beyond individual careers to families and communities.” The discussions at the German Nursing Career Fair reinforced the importance of transparent information, structured preparation, and language readiness in enabling nurses to make informed decisions about global careers and long-term professional growth.

January 16, 2026 | New Job Opportunity

Frontage Laboratories’ New GMP Facility Fully Operational

Frontage Laboratories, Inc., a leading contract development and manufacturing organization (CDMO) announced that its new facility opened in May 2025 had completed GMP facility validation in October 2025, and has been fully operational with on-going Clinical Phase III, PPQ batches and small-scale commercial manufacturing. This new facility is dedicated to drug development and clinical & commercial manufacturing including sterile, oral solid, and liquid dosage forms. This manufacturing facility contains GMP manufacturing rooms per ISO classification, including containment suites for handling high potency compounds, dedicated manufacturing suites for non-sterile products (tablets, capsules, ointments, gels and oral liquids), aseptic suites for sterile products (e.g., vials, syringes, and cartridges), formulation development rooms, and analytical and microbiology laboratories. Frontage's investment in expansion includes three (3) new automated aseptic filling machines (vials, syringes, and cartridges), 2 new additional isolators for potent compound handling and aseptic filling, a new Gerties roller compactor, a new Korsch Tablet press, Xcelodose system, and a labeler with several other additional supporting new equipment. These additions enable Frontage to offer efficiency, quality and reduce the time required to bring critical medicines to market. By integrating advanced technologies and capabilities with a comprehensive quality management system, Frontage provides an efficient, reliable manufacturing solution for customers, particularly small and mid-sized pharmaceutical companies aiming for rapid clinical trials or market entry. "With this fully operational GMP facility with newly installed commercial scale equipment and systems, Frontage bolsters its role as a comprehensive partner, supporting clients to achieve faster time-to-market by managing every step of the pharmaceutical development and manufacturing process," said Dr. Song Li, Chairman of Frontage. "Our pharmaceutical solutions offerings will support customers in optimizing both cost and quality, and support patients globally."

January 15, 2026 | New Job Opportunity

Hearing Aid Specialist Rising on Top Jobs' Lists

The International Hearing Society is pleased to share that the U.S. News & World Report (USNWR) January 12 edition once again ranked Hearing Aid Specialist as a best job for 2026, based on their findings from the U.S. Bureau of Labor Statistics and in-house reporting. Hearing Aid Specialist moved up in every category, including a twenty-four-point swing on their 100 Best Jobs list, cracking the top fifty. The January report examined jobs with the largest number and percentage of projected openings from 2023 to 2033, as determined by the U.S. Bureau of Labor Statistics. The Hearing Aid Specialist profession made several top rankings in the Report: #45 in 100 Best Jobs, #14 in Highest-Paying Jobs Without A Degree, #6 in Best Jobs Without A College Degree, #18 in Best Health Care Jobs, and #25 in Best STEM Jobs. The International Hearing Society (IHS), which celebrates its 75th anniversary this year, is a professional association dedicated to the support, education, and advancement of hearing healthcare professionals, and is primed to meet the growing demand for this important profession. IHS President Michael Andreozzi, BS, BC-HIS, said, "I am so pleased to see Hearing Aid Specialist on so many of the 2026 USNWR Top Career Rankings. With a growing understanding of the health and safety implications of untreated hearing loss, paired with technological advances for hearing aids, consumers are more in need now than ever of information on how to best address their hearing loss. Hearing Aid Specialists play a vital role in helping people identify their personal communication needs, navigate the many options on the market with precision, expertise, and compassion, and provide counseling and support. I encourage caring individuals who are looking for a stable career where they can make a meaningful difference in the lives of others, to consider this unique and rewarding profession of Hearing Aid Specialist." What is a Hearing Aid Specialist? A Hearing Aid Specialist is a licensed professional trained to conduct hearing evaluations, screen for conditions indicating the need for physician referral, identify common types of hearing loss, and provide solutions, including the use of hearing aids and other interventions. Most Hearing Aid Specialists are trained through an apprenticeship model – making this a highly accessible career choice. Others may complete an associates degree program, and all must comply with state licensing requirements. Executive Director of the International Hearing Society Alissa Parady, CAE, said, "Opportunities are vast for those considering a new career as a Hearing Aid Specialist. With strong demand for skilled professionals and an accessible path into the field, this profession offers an excellent alternative to a four-year degree and an exciting opportunity for those ready to make a meaningful career change. Helping individuals reconnect with loved ones, improve their health outcomes, and stay fully engaged in their professional lives work, provides high levels of job satisfaction and personal fulfillment."

Page 1 of 49

Featured Recruiters